110RO Mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody–drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): Additional data from BEHOLD-1 study

B7-H4 is highly expressed in OC and EC. Mo-Rez (GSK5733584), a novel ADC consisting of a humanized IgG1 monoclonal anti-B7-H4 antibody conjugated to a cyclopropyl-modified topoisomerase 1 inhibitor (drug–antibody ratio: 6), showed promising activity in global PROC and advanced/recurrent EC populations in BEHOLD-1 (NCT06431594). Here, we report additional data from the BEHOLD-1 study of Mo-Rez monotherapy, including B7-H4 expression and Mo-Rez activity by prior treatment.